How much has Pyxis Oncology stock gained year-to-date?

The stock has gained 54.78% year-to-date.

Is Pyxis Oncology considered a cheap stock?

Yes, the stock trades below $5, placing it among cheap biotech stocks.

Analysts See 293% Upside in Pyxis Oncology (PYXS)

Q: Why do analysts expect such a large upside?

Due to a busy clinical calendar with key data readouts from the company's lead oncology program.

Analysts expect Pyxis Oncology (PYXS) to rise 293.30% further, even after a 54.78% year-to-date gain. The conviction is based on a busy clinical calendar with key data readouts from the lead program.

June 10, 2026

2 min read

Source: Insider Monkey

Key Numbers

ytd gain

54.78%

upside

293.30%

Analysts see an additional 293.30% upside for Pyxis Oncology (NASDAQ:PYXS), which has already gained 54.78% year-to-date. This high conviction is rooted in a busy clinical calendar, with key data readouts from the company's lead program expected soon.

Rating Details

Analysts maintain a positive rating with a price target implying nearly three times the current value. The specific analyst or firm was not disclosed, but the consensus reflects broad optimism.

Analyst Rationale

Analysts focus on near-term clinical catalysts, primarily data readouts from Pyxis Oncology's lead program. The company operates in oncology, developing novel immunotherapies.

Context

This optimism comes despite the stock trading below $5, placing it among cheap biotech stocks. The strong YTD performance (up 54.78%) already reflects some positive expectations, but analysts see room for further gains.

What to Make of It

The rating hinges on upcoming clinical trial results. Any delay or negative outcome could impact the price target. Investors should assess the risks inherent in clinical-stage development.

Frequently Asked Questions

A specific price target was not given, but analysts expect a 293.30% upside from the current price.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.